Express News | Amylyx Pharmaceuticals Shares up 1.7% on Late-Stage Trial Update for Low-Blood Sugar Drug
Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
Express News | Amylyx Pharmaceuticals Inc - First Participant in Lucidity Trial Expected in Q1 2025
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Express News | Amylyx Pharmaceuticals Announces Pivotal Phase 3 Lucidity Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
